From the USA: Novel Imaging Technique Accurate for Detecting Clear-Cell Renal Cell Cancer

⁸⁹Zr-labeled monoclonal antibody ([⁸⁹Zr]Zr-girentuximab) for positron emission tomography-computed tomography (PET-CT) is accurate for detecting patients with clear-cell renal cell carcinoma, according to a study published online in the October issue of The Lancet Oncology.

Brian Shuch, M.D., from the University of California Los Angeles, and colleagues conducted a multicenter, phase 3 trial at 36 research hospitals and practices across nine countries to examine [⁸⁹Zr]Zr-girentuximab PET-CT imaging for detection and characterization of clear-cell renal cell carcinoma. Three hundred patients aged 18 years or older with an indeterminate renal mass 7 cm or smaller (cT1) suspicious for clear-cell renal cell carcinoma and scheduled for nephrectomy received a single dose of [⁸⁹Zr]Zr-girentuximab intravenously followed by abdominal PET-CT imaging. Surgery was performed up to 90 days after [⁸⁹Zr]Zr-girentuximab administration.

Source: Advances and More licensed by HealthDay

https://advancesandmore.com/advances_article.htm?id=ZTNiMmYxNjEtNGNmMy00NzQ0LTllNzMtNWQxMDQ1Zjg4Yzhl&client=Nw%3D%3D&section=undefined